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Abstract
Affinity-based techniques, both for enrichment or depletion of proteins of interest, suffer from unwanted interactions
between the bait or matrix material and molecules different from the original target. This effect was quantitatively
studied by applying two common procedures for the depletion of albumin/gamma immunoglobulin to human
cerebrospinal fluid. Proteins of the depleted and the column-bound fraction were identified by mass spectrometry,
employing 18O labeling for quantitation of their abundance. To different extents, the depletion procedures
caused the loss of proteins previously suggested as biomarker candidates for neurological diseases. This is an
important phenomenon to consider when quantifying protein levels in biological fluids.
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Background
Affinity chromatography-based enrichment or depletion
techniques are of great importance in both basic and ap-
plied protein research in the biomedical field. Many dif-
ferent materials are utilized for binding specific targets -
ranging from native (e.g., immunoglobulins), or tagged
proteins/protein domains to smaller structures such as
synthetic peptides. Protein-protein interaction studies in
or protein purification from complex environments are
unthinkable without co-immunoprecipitation protocols
or other types of pull-down assays. On the other hand,
the search for biomarkers using proteomic methods can
be facilitated after depletion of highly abundant proteins
from biological fluids [1]. However, affinity-based tech-
niques suffer from an annoying disadvantage: non-
specific binding, either to the bait molecule or to the
matrix material, can significantly impair the quality of
the experiment. False positive results may arise or poten-
tial biomarkers can be removed from the biological
sample.
Human cerebrospinal fluid (hCSF) experiences increas-
ing interest as a source of biomarkers of neurological dis-
eases [2]. In the present contribution, two common
principles of albumin and immunoglobulin removal,
Cibacron Blue/Protein A (CB-D)- and antibody/Protein
G-based (AB-D) depletion, have been tested with respect
to their specificity when applied to hCSF. Although the
problem is qualitatively described in the literature, quanti-
tative data on non-specific binding occurring in affinity
approaches (which are important, e.g., for the reliable
identification of potential biomarkers) are not available so
far. Here, we use mass spectrometry (MS)-based protein
identification combined with stable isotope labeling by in-
corporation of 18O for relative quantification of co-
depleted proteins [3]. The results demonstrate that the
abundance of numerous proteins, including many bio-
marker candidates, is strongly influenced by depletion
procedures.
Co-depletion removes potential biomarker proteins
The depletion of albumin and immunoglobulins was ac-
complished by application of two different approaches,
CB-D and AB-D (Additional file 1: for experimental de-
tails). Briefly, the column-bound and depleted fractions
were collected and separated by one-dimensional so-
dium dodecyl sulfate gel electrophoresis. In-gel digestion
of both lanes using trypsin was performed for the
column-bound fraction in H2
18O and for the flow-
through fraction in normal water. Peptide extracts ori-
ginating from gel slices of identical molecular weight
were combined. Subsequent mass spectrometry identified
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the proteins and their respective depletion ratios R = Ic/Id
(mass spectra intensities of column-bound vs. depleted
fraction) via analysis of the isotope distribution.
The Coomassie-stained gels (Additional file 2: Figure S1)
demonstrate that both depletion procedures used for the
experiments removed albumin and IgGs from the hCSF
sample. The efficacy of albumin depletion was determined
by densitometric analysis of the main albumin gel bands
(Icolumn-bound/Idepleted = 0.59 for CB-D, 2.41 for AB-D).
The gel bands of the column-bound fraction indicate
that there is considerable co-depletion of proteins, in
particular after application of CB-D. Preliminary experi-
ments directed at analyzing the identities of proteins in
the column-bound fractions revealed overwhelming
dominance of albumin fragments in gel bands with
apparent molecular masses ≤64 kDa. Thus, MS-based
quantitative evaluation was carried out for gel slices
covering all proteins with apparent molecular masses
above the albumin band. An overview of the vulner-
ability of both procedures for co-depletion is shown
in Fig. 1, which presents the distribution of the inci-
dence of depletion ratios R.
For the CB-D method, 17 of the entries with R ≥ 50
refer to immunoglobulins (24 entries in total, Additional
file 3: Table S1) identified with ratios indicating almost
complete elimination from the sample. However, there is
also efficient co-depletion: 28 proteins different from im-
munoglobulins are found at more than 50-fold excess in
the column-bound fraction also indicating virtually total
loss in the depleted fraction. These 28 gene products in-
clude 24 proteins (selection given in Table 1) which have
been previously classified as potential biomarkers for
specific (preferentially neurodegenerative) diseases. The
candidate marker proteins with the highest depletion-
caused loss include junction plakoglobin (suggested as
a marker of atherosclerosis [4]), colony-stimulating
factor 1 receptor (marker candidate of amyotrophic
lateral sclerosis [5]) and plasminogen (marker candi-
date of Alzheimer’s disease (AD) [6]). Differential ex-
pression has been demonstrated for complement C5,
ectonucleotide pyrophosphatase/phosphodiesterase family
member 2 and α-2-macroglobulin in the CSF of CNS
lymphoma patients as well as for complement C7 and co-
agulation factor V in choroid plexus tumors [7].
Much lower protein loss due to co-depletion was ob-
served after antibody-based depletion (Table 1, complete
results in Additional file 4: Table S2). Nevertheless, sev-
eral potential biomarker proteins were also found to
dominate the column-bound fractions. Desmoglein-1,
Fig. 1 Distribution of ratios R (R = Ic/Id, Ic, Id, mass spectrometry
signal intensities of proteins [mean of corresponding peptide ratios]
in column-bound/depleted fractions) for Cibacron Blue/Protein
A- (blue filled circles) and antibody/Protein G-based depletion
(red open circles)
Table 1 Proteins identified in column-binding fractions (selection)
Protein Accession R Reference
Cibacron Blue/Protein A – based
depletion
Junction plakoglobin sp|P14923 >50 [4]
Complement component C7 sp|P10643 >50 [7]
Complement C5 sp|P01031 >50 [7]







Alpha-2-macroglobulin sp|P01023 >50 [6]
Coagulation factor V sp|P12259 >50 [7]
Complement factor B tr|B4E1Z4 >50 [6]
Complement C1r subcomponent sp|P00736 >50 [7]
Gelsolin sp|P06396 >50 [6]
Isoform 2 of amyloid-like protein 1 sp|P51693-2 >50 [6]
Fibulin-1 sp|P23142 >50 [7]
Complement C2 sp|P06681 >50 [6]
Complement factor H sp|P08603 >50 [9]
Neurexin-2-alpha sp|Q9P2S2 >50 [8]
Complement C3 sp|P01024 >50 [8]
Antibody/Protein G – based
depletion
Desmoglein-1 sp|Q02413 >50 [8]
Calmodulin-like protein 5 sp|Q9NZT1 50 > R > 20 [8]
Collagen alpha-1(I) chain sp|P02452 20 > R > 2 [8]
Collagen, alpha-2(I) chain tr|F5H299 20 > R > 2 [6]
Complement factor H sp|P08603 2 > R > 0.5 [9]
Plasminogen sp|P00747 2 > R > 0.5 [8]
Alpha-1-antitrypsin sp|P01009 2 > R > 0.5 [9]
Isoform 2 of calsyntenin-1 sp|O94985-2 2 > R > 0.5 [9]
Accession, accession number in SwissProt (sp)/Tremble (tr) data base; R, MS
signal intensity ratio Icolumn-bound/Idepleted; Ref., reference suggesting eligibility
as a biomarker; complete lists of identified proteins available as additional files
(Additional files 3 and 4: Tables S1 and S2)
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calmodulin-like protein 5, collagen alpha-1(I) chain and
plasminogen have been identified as marker candidates
for multiple sclerosis [8] while increased levels of α-1-
antitrypsin and calsyntenin-1 (isoform 2) have been
found in the CSF of AD and Parkinson’s disease patients,
respectively [9].
Depletion protocols: caution advised
Non-specific binding is inherent in affinity-based en-
richment or depletion protocols. The efficacy of the
Cibracon Blue/Protein A-based procedure for im-
munoglobulin depletion was found significantly higher
as compared to the antibody-based method which in
turn showed a lower co-depletion. For albumin and
immunoglobulins, non-specific association overlaps
with the functional binding of these proteins to their
target molecules present in biological fluids or cells.
Recent data obtained using identical depletion tech-
niques for canine CSF indicate that indeed both phe-
nomena occur [10]. However, for the practical problem of
the depletion of highly abundant proteins, it is obviously
irrelevant which mechanisms (non-specific binding to
matrix/bait or specific binding to bait molecule) cause the
observed co-depletion.
Conclusion
For affinity approaches, there is a lack of quantitative
data on unwanted removal (or enrichment) of proteins,
although this information is of crucial importance for
assessing the quality of an experiment and the reliability
of its results. With respect to depletion procedures, our
quantitative approach demonstrated that many proteins
previously identified as potential biomarkers are com-
pletely removed from the hCSF sample, often with even
higher efficiency than the original target of the proced-
ure. The supplemental tables give (non-exhaustive) lists
of proteins that were particularly affected in these exper-
iments. Taking this into account, it is obvious that the
quantification of the abundance of many proteins is
prone to major systematic errors when the sample
preparation includes depletion protocols of the types in-
vestigated here. Moreover, the presented data, although
obtained for depletion procedures, can also be relevant
for approaches based on similar protocols for affinity
enrichment.
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